首页 News 正文

BSM Squibb acquires Karuna for $14 billion to acquire potential "first in class" therapies

凉亭之中净
1243 0 0

Bristol Myers Squibb and Karuna Therapeutics announced a final acquisition agreement, as Bristol Myers Squibb acquires potential first in class therapies from Karuna for $14 billion. According to the agreement, Bristol Myers Squibb agreed to acquire Karuna Company for a total amount of approximately $14 billion. Through this acquisition, Bristol Myers Squibb will acquire Karuna's potential "first in class" therapy, KarXT (xenomeline therapy), which has been accepted by the US FDA for a new drug application (NDA) for the treatment of adult schizophrenia. The PDUFA target date is September 26, 2024. According to the press release, if approved, KarXT will become the first new mechanism drug used to treat schizophrenia in decades.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

凉亭之中净 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    1